Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate

  • Aptevo Therapeutics Inc APVO announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve Acute Myeloid Leukemia (AML) patients. 
  • The data also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.
  • Clinical activity was observed in both monotherapy and combination cohorts.
  • CRS was observed in fewer than one-quarter of patients within the safety population and, in most cases, was mild or moderate (grade 1 or 2) and manageable.
  • In the Phase 1b trial cohort 2, 16 response-evaluable patients received the combination therapy of venetoclax and azacitidine with APVO436, and 75% experienced clinical benefit. 
  • 100% of patients in this cohort who had not received venetoclax previously experienced clinical benefit.
  • Aptevo plans to initiate a Phase 2 trial in the second half of 2023 to further evaluate APVO436 in combination with venetoclax and azacitidine among frontline and relapsed/refractory AML patients who are venetoclax treatment naïve.
  • Price Action: APVO shares are up 65% at $5.66 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!